In a sweeping expansion of its cancer drug portfolio, global biopharmaceutical powerhouse Ipsen SAS announced Wednesday that it will acquire French biotech firm ImCheck Therapeutics for up to €1 billion ($1.16 billion), signaling one of the year’s most high-stakes oncology deals.

The transaction, which draws in a consortium of French, European, and U.S. investors, includes an upfront payment of €350 million, with additional milestone-based payouts tied to regulatory and commercial success. The acquisition positions Ipsen to deepen its presence in the global oncology market and push forward groundbreaking immunotherapy research.

Strategic Push Into Cancer Innovation

Ipsen, a Paris-listed pharmaceutical company on Euronext, said the deal is part of its aggressive strategy to broaden its oncology pipeline. At the heart of the acquisition lies ICT01, a clinical-stage program developed by ImCheck that targets acute myeloid leukemia (AML) — an aggressive blood and bone marrow cancer.

David Loew, Ipsen’s Chief Executive Officer, said the acquisition reinforces the company’s mission to bring transformative cancer therapies to patients worldwide.

“The acquisition of ImCheck Therapeutics presents an opportunity for us to expand our oncology pipeline and underscores our commitment to patients,” Loew stated. “With ICT01’s promising data and Ipsen’s development expertise, we aim to launch a Phase IIb/III trial by 2026.”

Global Investors Cash Out

Under the deal, ImCheck shareholders — including Kurma Partners, EQT Life Sciences, and Pfizer — will receive the initial €350 million payout. French investors Eurazeo, Bpifrance, and Andera Partners are also among the beneficiaries, alongside Belgium’s Gimv Life Sciences and Germany’s Earlybird Venture Capital, Boehringer Ingelheim Venture Fund, Wellington Partners, and Pureos Bioventures.

From across the Atlantic, Pfizer Ventures, Invus, Agent Capital, Alexandria Venture Investments, and Blood Cancer United will exit their stakes in the French biotech after the acquisition closes.

Massive Returns for Early Backers

The deal marks a particularly lucrative exit for early investors. Gimv Life Sciences revealed it could see more than seven times its original investment if ImCheck achieves all outlined milestones. Meanwhile, Kurma Partners, which helped found ImCheck in 2015 and backed all subsequent funding rounds, called the deal a major validation of long-term biotech innovation in Europe.

Other investors, including EQT Life Sciences and Bpifrance, declined to disclose the size of their initial investments but expressed optimism about the deal’s global impact on cancer therapeutics.

Legal Counsel and Next Steps

Legal heavyweights are steering the cross-border transaction: Allen Overy Shearman Sterling is advising Ipsen, while Goodwin Procter LLP and Dentons are representing ImCheck and its shareholders.

Once finalized, the acquisition will make ImCheck a fully integrated part of Ipsen’s oncology research division, accelerating the company’s march into next-generation immunotherapies.

With €1 billion on the line, Ipsen’s bold move could redefine Europe’s footprint in the global cancer treatment race — a deal that transforms not just a portfolio, but potentially, the future of oncology innovation itself.